Risk For Testicular Cancer Increases With Genetic Copy-Number Variants

Genetics clearly plays a role in cancer development and progression, but the reason that a certain mutation leads to one cancer and not another is less clear. Furthermore, no links have been found between any cancer and a type of genetic change called “copy-number variants,” or CNVs. Now, a new study published by Cell Press in The American Journal of Human Genetics identifies CNVs associated with testicular cancer risk, but not with the risk of breast or colon cancer.

Some cancers, including breast and colon cancer, are caused by mutations that are passed from one generation to the next. However, most cancers, including testicular cancer, are sporadic - they arise without a family history of cancer. Many of these sporadic cancers result from genetic mutations in germ cells - the cells involved in reproduction - even though neither parent has the mutation. Scientists call these “de novo” mutations.

In order to identify rare de novo mutations associated with cancer risk, Dr. Kenneth Offit and colleagues searched for CNVs, which are duplications or deletions of one or more sections of DNA, in cancer patients and their cancer-free relatives. They found a significant increase in the number of rare de novo CNVs in individuals with testicular cancer as opposed to breast or colon cancer. Although such CNVs have been associated with autism and other neurocognitive and cardiovascular disorders, they were not previously known to be associated with cancer.

The authors propose that de novo changes (as opposed to those inherited from parents) might be indicative of conditions that have traditionally resulted in reduced fertility. Although modern treatment regimens allow more than 90% of men with testicular cancer to live long and reproductive lives, the condition traditionally left affected men childless. “We speculate that the paradigm of a de novo germline disease etiology may be less applicable to late-onset cancers,” says Offit, “in part explaining the lower frequency of de novo events we found in adult-onset breast and colon cancer cases.” Pinpointing the specific genetic changes that lead to cancer development will improve the understanding of the origins of cancer, leading to new treatment strategies and ultimately easing the burden on those afflicted with these diseases.

Risk factors for testicular cancer

Undescended testicle: One of the main risk factors for testicular cancer is a problem called cryptorchidism, or undescended testicle(s). Before birth, the testicles normally develop in the belly of the fetus and then move down (descend) into the scrotum before birth. But in about 3% of boys, the testicles do not move into the scrotum. Sometimes the testicle stays inside the belly. In other cases, the testicle starts to come down, but gets stuck in the groin.

Men who have had cryptorchidism are several times more likely to get testicular cancer than those who did not have the problem. The risk is higher for men with a testicle in the belly as opposed to one that has moved down at least part way. Among men with a history of this problem, most cancers start in the testicle that has not moved down. But about 1 out of 4 occurs in the normal testicle. Because of this, some doctors think that cryptorchidism is not the direct cause of testicular cancer. They believe that some other problem causes both the cancer risk and the cryptorchidism.

Most testicles will descend on their own in the child’s first year. Sometimes surgery (called orchiopexy) is needed to bring the testicle down into the scrotum. Surgery done when a child is younger may be more likely to reduce the risk of testicular cancer than surgery done when the child is older, but the best time to do this surgery is not clear.

Family history: A family history of testicular cancer increases the risk. If a man has the disease, there is a higher risk that his brothers or sons may also get it. But very few cases of testicular cancer are actually found in families.

HIV infection: There is some evidence that men infected with HIV (human immunodeficiency virus) have an increased risk of testicular cancer. This may be especially true for men who have AIDS. No other infections have been shown to increase testicular cancer risk.

CIS (carcinoma in situ): CIS is described in “What is testicular cancer?” It isn’t clear how often CIS in the testicles becomes cancer. It is sometimes found when a man is tested for infertility. It may also be found when a man has a testicle removed because of cryptorchidism. Radiation or surgery (to remove the testicle) is used to treat CIS. Since we don’t know how often CIS becomes true (invasive) cancer, it isn’t clear that treating CIS is a good idea. Some experts think that it may be better to wait and see if the disease gets worse or becomes a true cancer. This could allow many men with CIS to avoid the risks and side effects of treatment.

Cancer of the other testicle: Men who have been cured of cancer in one testicle have an increased risk (about a 3% to 4% chance) of getting cancer in the other testicle.

Age: About half of testicular cancers occur in men between the ages of 20 and 34. But this cancer can affect males of any age, including infants and older men

Race and ethnicity: White American men are about 5 times more likely to get testicular cancer than are African-American men. Whites have more than 3 times the risk of Asian-American and American Indian men. The risk for Hispanics falls between that of Asians and non-Hispanic whites. The reason for these differences is not known.

Body size: Some studies have that the risk of testicular cancer is somewhat higher in tall men but other studies have not shown a link.


Some facts about testicular cancer

Cancer of the testicle can develop in one or both testicles in males of any age, including infants and elderly men. Almost half of all cases of testicular cancer are in men between the ages of 20 and 34.

Testicular cancer is not common; a man’s lifetime chance of getting it is about 1 in 270. The risk of dying from this cancer is about 1 in 5,000.

MediLexicon, Intl., 5 Aug. 2012. Web.

Provided by ArmMed Media